Forcing a single clinical supply model across APAC creates delays, costs, and regulatory risks. This presentation addresses regional complexities through flexible strategies and local collaboration.
- Model Selection: Evaluating central, regional, and hybrid supply frameworks.
- Streamlined Logistics: Bridging gaps between sourcing, compliance, and local distribution.
- Risk Mitigation: Overcoming cross-border bottlenecks and critical documentation challenges.
- Strategic Value: Balancing speed, cost, and long-term partner alignment over transactional relationships.
在亚太地区强推单一的临床供应链模型会导致延误、高昂成本和合规风险。本演讲将通过灵活的战略与本地化合作，探讨并解决这些区域复杂性问题。
- 模式选择：评估集中式、区域式以及混合式的供应链架构。
- 高效物流：消除采购、合规与本地分销之间的断层。
- 风险缓解：克服跨境瓶颈与关键文件审查带来的挑战。
- 战略价值：权衡速度与成本，建立长期的伙伴协作，而非单纯的业务交易
Many countries across the globe have enacted privacy laws and now Healthcare Authorities and Ethics Committees mandate that Clinical Trial Applications contain appropriate data privacy language. The good news is that it is simple in the Life Science industry because Good Clinical Practices have always protected the Rights of the Patients since the Code of Nuremberg in 1949. Participants will understand how to do it right the first time, they will learn the key points of attention, so the clinical trial is not delayed.
全球许多国家已颁布隐私法。目前，各国医疗卫生当局和伦理委员会均强制要求临床试验申请（CTA）中包含适当的数据隐私表述。值得庆幸的是，生命科学行业在此方面有深厚积累——自1949年《纽伦堡法典》问世以来，”临床试验规范“（GCP）就一直致力于保护患者权益。本演讲/课程将帮助参会者了解如何从源头实现合规的正确路径，并深度剖析关键风控点，以避免临床试验的延误。
Forcing a single clinical supply model across APAC creates delays, costs, and regulatory risks. This presentation addresses regional complexities through flexible strategies and local collaboration.
- Model Selection: Evaluating central, regional, and hybrid supply frameworks.
- Streamlined Logistics: Bridging gaps between sourcing, compliance, and local distribution.
- Risk Mitigation: Overcoming cross-border bottlenecks and critical documentation challenges.
- Strategic Value: Balancing speed, cost, and long-term partner alignment over transactional relationships.
在亚太地区强推单一的临床供应链模型会导致延误、高昂成本和合规风险。本演讲将通过灵活的战略与本地化合作，探讨并解决这些区域复杂性问题。
- 模式选择：评估集中式、区域式以及混合式的供应链架构。
- 高效物流：消除采购、合规与本地分销之间的断层。
- 风险缓解：克服跨境瓶颈与关键文件审查带来的挑战。
- 战略价值：权衡速度与成本，建立长期的伙伴协作，而非单纯的业务交易
Chinese biotech is moving faster than ever from innovation to global ambition — but the challenge now goes beyond developing a differentiated asset. It’s proving that asset’s value early, generating globally credible clinical data, and reaching the right international partners before momentum fades. Drawing on real-world case studies, this session examines how delays at proof-of-concept erode value, how regulatory and operational efficiency compress development timelines, and how Chinese biotechs can expand globally without slowing execution. Attendees will gain practical insight into how faster PoC, stronger patient access, efficient global trial deployment, and high-quality international data strengthen partnering discussions and make assets more attractive to global pharma.
中国生物医药产业正以前所未有的速度从“本土创新”迈向“全球雄心”。然而，企业如今面临的挑战已不仅限于研发具有差异化的资产，更在于如何在早期证明资产价值、生成具备全球公信力的临床数据，并在市场热度消退前精准对接国际合作伙伴。本议程将结合真实世界案例研究，深入探讨概念验证（PoC）阶段的延迟如何侵蚀资产价值、如何通过提升监管与运营效率来压缩研发周期，以及中国药企如何在不牺牲执行速度的前提下实现全球化扩展。参会者将获得极具实用价值的行业洞察，明确如何通过加速PoC进程、强化患者招募、高效部署全球临床试验以及获取高质量国际数据，来增加商务谈判筹码，从而让管线资产对跨国药企（Global Pharma）更具吸引力。
